- Home
- MNPR vs AMRN Comparison
MNPR vs AMRN Comparison
Compare MNPR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | AMRN |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 304.3M |
| IPO Year | 2019 | 1998 |
Fundamental Metrics
Financial Performance| Metric | MNPR | AMRN |
|---|---|---|
| Price | $58.91 | $14.43 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 11 | 1 |
| Target Price | ★ $107.00 | $12.00 |
| AVG Volume (30 Days) | ★ 160.0K | 78.5K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.99 | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $28.40 | $11.03 |
| 52 Week High | $105.00 | $20.90 |
Technical Indicators
Market Signals| Indicator | MNPR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 47.80 |
| Support Level | $50.60 | $13.55 |
| Resistance Level | $61.51 | $16.91 |
| Average True Range (ATR) | 4.38 | 0.66 |
| MACD | 0.47 | 0.04 |
| Stochastic Oscillator | 51.18 | 59.92 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.